RTI’s Silver Lining: Sterling Bone Void Approval Sends Stock Up 21% In August
This article was originally published in The Gray Sheet
Regeneration Technologies' receipt of FDA clearance for the Sterling xenograft bone void fillers helped push the firm's stock price up 21% to $9.25 in August
You may also be interested in...
Regeneration Technologies, Inc. (RTI) will consider creating an independent sales force after Medtronic placed fewer orders during Q1, causing RTI spinal revenue to drop by nearly half
Cardiac Science's merger with Quinton Cardiology Systems will eliminate debt to facilitate competition in the public-access defibrillator market, the firm says
COVID-19 Vaccines: ACIP’s Allocation Proposal Prioritizes Long-Term Care Residents, Essential Workers
First group to receive vaccine would comprise health care personnel and residents of long-term care facilities; next in line are non-health care essential workers, who would take priority over adults with high-risk medical conditions and those ages 65 years and older, according to the CDC advisory committee’s proposed allocation framework.